In this episode of the Psychedelic Medicine Podcast Kayla Knopp joins to explore the topic of MDMA-Assisted Couples Therapy. Dr. Kayla Knopp is a clinical psychologist and researcher specializing in non-traditional couples and relationships. She specializes in making couple therapies more inclusive, accessible, and effective, including MDMA- and ketamine-assisted couple therapy.
Read MoreIn this episode of the Psychedelic Medicine Podcast, Dr. Ben Sessa joins to share results of his investigation into MDMA-assisted psychotherapy for alcohol use disorder. Dr. Sessa is a trained MDMA and psilocybin therapist and the chief medical officer at Awakn Life Sciences, a biotechnology company researching, developing, and commercializing therapeutics to treat addiction with specific attention on alcohol use disorder in the near-term.
Read MoreIn this episode of the Psychedelic Medicine Podcast (formerly the Plant Medicine Podcast), Rick Doblin joins to discuss the past, present, and future of MDMA-assisted therapy. Rick Doblin is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies. He received his doctorate in public policy from Harvard and has also studied under the father of transpersonal psychology Stanislav Grof. Through MAPS, Rick aspires to develop legal contexts for beneficial uses of psychedelics and marijuana as prescription medicines, but also for self-development and personal growth in otherwise healthy individuals.
Read MoreThis episode of the Plant Medicine Podcast features a conversation with Shannon Carlin, MA, LMFT, to discuss how to become an MDMA-assisted therapist, including a discussion of the MAPS training program. Shannon is the Director and Head of Training and Supervision at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit where she oversees the development and implementation of clinical training programs that prepare mental health and medical professionals to deliver MDMA-assisted psychotherapy in approved clinical settings. Shannon started working with MAPS in 2011 before joining MAPS PBC in 2016.
Read MoreIn this episode, Dr. Malcolm discusses how antidepressants react with MDMA, psilocybin, DMT, 5-MeO-DMT, ayahuasca, and ketamine. He also explains the risk profiles for interactions between psychedelics and medications such as benzodiazepines, sleep medication, antipsychotics, and lithium.
Read MoreIn this episode, Dr. Malcolm discusses how antidepressants react with MDMA, psilocybin, DMT, 5-MeO-DMT, ayahuasca, and ketamine. He also explains the risk profiles for interactions between psychedelics and medications such as benzodiazepines, sleep medication, antipsychotics, and lithium.
Read MoreNatalie Ginsberg is the director of policy and advocacy at the Multidisciplinary Association for Psychadelic Studies (MAPS). She works hard to disentangle science from political partisanship on Capitol Hill, the United Nations, and beyond. Today, she is joining us to discuss the history and current legality of MDMA.
Read MoreShannon Carlin is the associate director of training and supervision at the MAPS Public Benefit Corp. In this role, she oversees the development and implementation of the programs that prepare mental health and medical professionals to deliver MDMA assisted psychotherapy in approved clinical settings.
Read MoreMarcela Ot'alora G is a psychotherapist with over 20 years of experience working with trauma, specifically PTSD. Having dedicated her professional life to teaching and research, Marcela has served as principle investigator and therapist on various phase-II and phase-III MDMA assisted psychotherapy studies.
Read MoreIn today’s patient experience episode, Steven tells us about a therapeutic use of MDMA that you may not have heard of. A medical practitioner himself, Steven understands his own condition of IBS very well and what standard treatment is. However, when all these failed to produce results, Steven took the chance and set out to discover how he could better treat his condition.
Read More
